Alpine Immune Sciences/ALPN

$30.51

-2.39%
-
1D1W1MYTD1YMAX

About Alpine Immune Sciences

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Company's scientific platform uses a directed evolution process to convert native immune system proteins from the immunoglobulin super family (IgSF) into multi-targeted therapeutics capable of modulating the human immune system. The Company’s product candidates include ALPN-101, ALPN-202 and ALPN-303. ALPN-101 is a dual inducible T cell costimulator (ICOS) and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Its oncology program is ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. ALPN-303 is a dual B-cell cytokine antagonist for the treatment of B-cell mediated diseases.
Ticker
ALPN
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Mitchell Gold
Employees
126
Headquarters
Seattle, United States

ALPN Metrics

BasicAdvanced
$2.05B
Market cap
-
P/E ratio
-$1.27
EPS
1.09
Beta
-
Dividend rate

What the Analysts think about ALPN

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 7 analysts.
10.03% upside
High $44.00
Low $29.00
$30.51
Current price
$33.57
Average price target

ALPN Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-117% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$10M
17.65%
Net income
$-11.7M
-10.69%
Profit margin
-117%
-24.08%

ALPN Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 28.24%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.41
-$0.28
-$0.27
-$0.24
-
Expected
-$0.27
-$0.37
-$0.37
-$0.33
-$0.34
Surprise
52.99%
-24.45%
-27.87%
-28.24%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Alpine Immune Sciences stock

Buy or sell Alpine Immune Sciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing